Publications by authors named "Blair S Allais"
Article Synopsis
- * Conducting large-scale studies and improving diagnostic criteria can lead to better treatments and patient care, as these adverse events are linked to longer survival rates.
- * Collaboration among specialists, particularly dermatologists, is essential for enhancing research and care strategies for cancer patients experiencing these skin-related side effects.
Article Synopsis
- Protein kinase inhibitors and immunotherapy have significantly improved treatment outcomes for advanced melanoma, but they also introduce various drug-related toxicities.
- This review highlights dermatologic adverse events associated with targeted therapies (like BRAF and MEK inhibitors) and immunotherapy, including talimogene laherparepvec.
- Recognizing and managing these skin-related toxicities is crucial since they can affect patients' quality of life and are linked to treatment response and survival rates.
Background: Although superficial spreading melanomas (SSM) are diagnosed as thinner lesions, nodular melanomas (NM) have a more rapid growth rate and are biologically more aggressive compared with other histologic subtypes.
Objective: To determine the difference in 5-year relative survival in patients with NM and SSM at the same Breslow depth and TNM stage.
Methods: A population-based cross-sectional analysis compared the 5-year relative survival of patients with NM and SSM using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)∗Stat software (version 8.